Quarterly report pursuant to Section 13 or 15(d)

Business Combinations - Additional Information (Detail)

v3.22.1
Business Combinations - Additional Information (Detail) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 01, 2022
Sep. 14, 2021
Mar. 31, 2022
Dec. 31, 2021
March 2022 Acquisition [Member]        
Business Acquisition [Line Items]        
Total consideration $ 5,844,000      
Equity consideration at closing 1,929,000      
Deferred consideration 2,707,000      
Settlement of pre-existing receivable 976,000      
Acquired cash 684,000      
Contingent earnout 3,015,000      
Tax deductible goodwill, acquisition 2,842,000      
Transaction cost 270,000      
March 2022 Acquisition [Member] | General and Administrative Expense [Member]        
Business Acquisition [Line Items]        
Acquisition related expenses $ 270,000      
March 2022 Acquisition [Member] | Maximum [Member]        
Business Acquisition [Line Items]        
Estimated useful lives 10 years      
March 2022 Acquisition [Member] | Minimum [Member]        
Business Acquisition [Line Items]        
Estimated useful lives 2 years      
Pandologic Ltd [Member]        
Business Acquisition [Line Items]        
Contingent earnout   $ 30,000,000    
Pandologic Ltd [Member] | Contingent Consideration        
Business Acquisition [Line Items]        
Contingent earnout   26,400,000    
Pandologic Ltd [Member] | General and Administrative Expense [Member]        
Business Acquisition [Line Items]        
Acquisition related expenses       $ 2,161,000
Pandologic Ltd [Member] | Recognized in Compensation Expense Within General and Administrative Expense [Member]        
Business Acquisition [Line Items]        
Contingent earnout   3,600,000    
Pandologic Ltd [Member]        
Business Acquisition [Line Items]        
Total consideration   122,451,000    
Equity consideration at closing   31,500,000    
Deferred tax liability   $ 11,828,000 $ 0  
Deferred tax assets     0  
Goodwill not deductible for tax purposes     25,141,000  
Deferred tax assets, valuation allowance     $ 0  
Pandologic Ltd [Member] | Israeli [Member]        
Business Acquisition [Line Items]        
Tax rate   23.00% 12.00%  
Pandologic Ltd [Member] | Maximum [Member]        
Business Acquisition [Line Items]        
Estimated useful lives     7 years  
Pandologic Ltd [Member] | Minimum [Member]        
Business Acquisition [Line Items]        
Estimated useful lives     4 years  
Pandologic Ltd [Member] | Common Stock [Member]        
Business Acquisition [Line Items]        
Consideration equity interest issued number of shares     352,330  
Purchase Agreement [Member] | March 2022 Acquisition [Member]        
Business Acquisition [Line Items]        
Business acquisition, effective date of acquisition Mar. 01, 2022      
Business acquisition, percentage of ownership interests acquired 100.00%      
Business acquisition, date of acquisition agreement Mar. 01, 2022      
Total consideration $ 5,844,000      
Consideration upfront payment in cash 1,500,000      
Deferred cash payment 3,000,000      
Deferred consideration 2,707,000      
Settlement of pre-existing receivable (976,000)      
Acquired cash 684,000      
Purchase Agreement [Member] | March 2022 Acquisition [Member] | Maximum [Member]        
Business Acquisition [Line Items]        
Contingent earnout consideration 4,500,000      
Purchase Agreement [Member] | March 2022 Acquisition [Member] | Common Stock [Member]        
Business Acquisition [Line Items]        
Equity consideration at closing $ 1,929,000      
Consideration equity interest issued number of shares 116,550      
Merger Agreement [Member] | Pandologic Ltd [Member]        
Business Acquisition [Line Items]        
Business acquisition, effective date of acquisition   Sep. 14, 2021    
Business acquisition, percentage of ownership interests acquired   100.00%    
Business acquisition, date of acquisition agreement   Jul. 21, 2021    
Total consideration   $ 122,451,000    
Consideration upfront payment in cash   $ 58,733,000    
Business acquisition, name of acquired entity   PandoLogic.    
Merger Agreement [Member] | Pandologic Ltd [Member] | Maximum [Member]        
Business Acquisition [Line Items]        
Contingent earnout consideration   $ 65,000,000    
Merger Agreement [Member] | Pandologic Ltd [Member] | Common Stock [Member]        
Business Acquisition [Line Items]        
Equity consideration at closing   $ 31,500,000    
Consideration equity interest issued number of shares   1,704,822